Literature DB >> 10755056

Determinants of quality of life at first presentation with schizophrenia.

S Browne1, M Clarke, M Gervin, J L Waddington, C Larkin, E O'Callaghan.   

Abstract

BACKGROUND: Quality of life (QOL) has gained importance as a global measure of social and clinical outcome in schizophrenia. AIMS: To identify the clinical correlates of QOL at the time of first presentation with schizophrenia.
METHOD: Over two years, consecutive first-episode psychosis patients presenting to a catchment area psychiatric service underwent validated clinical assessments of premorbid adjustment, illness duration, symptoms and QOL.
RESULTS: At presentation, subjects already had a diminished QOL. Although independent of gender and age at onset of psychosis, QOL was influenced by premorbid adjustment, duration of untreated psychosis and symptoms.
CONCLUSIONS: Reducing the duration of untreated psychosis may have a beneficial effect on the subsequent QOL of patients presenting with schizophrenia. First-episode patients with a protracted duration of untreated psychosis or impaired premorbid adjustment may warrant specific treatment interventions to prevent the development of secondary handicaps.

Entities:  

Mesh:

Year:  2000        PMID: 10755056     DOI: 10.1192/bjp.176.2.173

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  28 in total

Review 1.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 2.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

3.  Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients.

Authors:  Michael Ritsner; Rena Kurs; Anatoly Gibel; Yael Ratner; Jean Endicott
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

4.  Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia.

Authors:  C W Law; Eric Y H Chen; Eric F C Cheung; Raymond C K Chan; Josephine G W S Wong; Cindy L K Lam; K F Leung; Molly S M Lo
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

5.  Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong.

Authors:  Frederick Ka Ching Yeung; Sunny Ho Wan Chan
Journal:  Qual Life Res       Date:  2006-09-07       Impact factor: 4.147

6.  Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis.

Authors:  Shaun M Eack; Christina E Newhill
Journal:  Schizophr Bull       Date:  2007-01-04       Impact factor: 9.306

7.  The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up.

Authors:  Nora S Vyas; Michael Hadjulis; Apostolos Vourdas; Patrick Byrne; Sophia Frangou
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

8.  The RAISE Connection Program for Early Psychosis: Secondary Outcomes and Mediators and Moderators of Improvement.

Authors:  Leslie Marino; Ilana Nossel; Jean C Choi; Keith Nuechterlein; Yuanjia Wang; Susan Essock; Melanie Bennett; Karen McNamara; Sapna Mendon; Lisa Dixon
Journal:  J Nerv Ment Dis       Date:  2015-05       Impact factor: 2.254

9.  Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.

Authors:  Omer Saatcioglu; Murat Kalkan; Nurhan Fistikci; Sakire Erek; Kasim Candas Kilic
Journal:  Psychiatr Q       Date:  2016-06

10.  Measurement of quality of life in schizophrenia: a comparison of two scales.

Authors:  Yvette Kusel; Richard Laugharne; Sian Perrington; Jan McKendrick; Deborah Stephenson; J Stockton-Henderson; Madeline Barley; R McCaul; Tom Burns
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-08-29       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.